Drawing on his technical expertise, Josh guides clients through complex patent matters involving a range of technology areas, including small molecule drugs, monoclonal antibodies, mRNA therapeutics, lipid nanoparticles, vaccines, CAR-T therapies, flow cytometry technology and polymer chemistry.

Josh’s patent procurement practice includes patent drafting, prosecution and worldwide portfolio management in the life sciences industry, including for Food and Drug Administration (FDA)-approved pharmaceutical products and products in ongoing Phase 3 clinical trials and products undergoing FDA regulatory review. He also provides freedom to operate analyses and opinions, due diligence and patent portfolio reviews.

Josh also represents pharmaceutical and biotechnology companies in patent litigation matters and pre-litigation due diligence. His litigation experience includes pharmaceutical litigation under the Hatch-Waxman Act on behalf of both innovator and generic pharmaceutical companies. He has also provided patent landscape analyses for biotechnology companies anticipating possible litigation under the Biologics Price Competition and Innovation Act (BPCIA).

Josh is not admitted to practice law in the Commonwealth of Massachusetts. His United States practice exclusively involves matters of federal law and matters in federal courts or before federal agencies, including the United States Patent and Trademark Office.